Cargando…

The involvement of Kras gene 3′-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis

BACKGROUND: Genetic variation of the Kras oncogene is a candidate factor for increasing susceptibility to carcinoma and modulating response of metastatic colorectal cancer (mCRC) patients treated with anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR). However, results from an inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ying, Hou-Qun, Wang, Feng, He, Bang-Shun, Pan, Yu-Qin, Gao, Tian-Yi, Xu, Ye-Qiong, Li, Rui, Deng, Qi-Wen, Sun, Hui-Lin, Wang, Shu-Kui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154892/ https://www.ncbi.nlm.nih.gov/pubmed/25210463 http://dx.doi.org/10.2147/OTT.S65496

Ejemplares similares

FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer
por: Ying, Hou-Qun, et al.
Publicado: (2015)

KRAS and VEGF gene 3'-UTR single nucleotide polymorphisms predicted susceptibility in colorectal cancer
por: Yang, Minnan, et al.
Publicado: (2017)

The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
por: Huang, Ching-Wen, et al.
Publicado: (2013)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
por: Chen, Yu, et al.
Publicado: (2015)

Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation
por: Ohishi, Tomokazu, et al.
Publicado: (2020)

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
por: Fiore, F Di, et al.
Publicado: (2008)

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
por: Gattenlöhner, S., et al.
Publicado: (2009)

Let-7 miRNA-binding site polymorphism in the KRAS 3(′)UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab
por: Kjersem, Janne B, et al.
Publicado: (2012)

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients
por: Naseem, Madiha, et al.
Publicado: (2021)

Let-7 microRNA-binding-site polymorphism in the 3′UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis
por: Langevin, Scott M, et al.
Publicado: (2014)

Association of HLA-G 3′UTR Polymorphisms with Response to First-Line FOLFIRI Treatment in Metastatic Colorectal Cancer
por: Scarabel, Lucia, et al.
Publicado: (2022)

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2016)

3′-UTR Polymorphisms in Thymidylate Synthase with Colorectal Cancer Prevalence and Prognosis
por: Jeon, Young-Joo, et al.
Publicado: (2021)

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
por: Kishiki, Tomokazu, et al.
Publicado: (2014)

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
por: Uhlyarik, Andrea, et al.
Publicado: (2020)

Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
por: Kim, Mi-Jung, et al.
Publicado: (2012)

The predictive value of KRAS and NRAS mutations in metastatic colorectal cancer
por: Eshraghi, Abbas, et al.
Publicado: (2020)

Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer
por: Knickelbein, Kyle, et al.
Publicado: (2018)

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
por: Chang, David Z, et al.
Publicado: (2009)

The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy
por: Ying, Hou-Qun, et al.
Publicado: (2015)

KRAS above and beyond – EGFR in pancreatic cancer
por: Siveke, Jens T., et al.
Publicado: (2012)

Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
por: Porru, Manuela, et al.
Publicado: (2018)

Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer
por: Ntavatzikos, Anastasios, et al.
Publicado: (2017)

Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
por: Ucar, Gokhan, et al.
Publicado: (2020)

KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer
por: Radanova, Maria, et al.
Publicado: (2023)

Circulating vitamin D binding protein, total, free and bioavailable 25-hydroxyvitamin D and risk of colorectal cancer
por: Ying, Hou-Qun, et al.
Publicado: (2015)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d
por: Huang, Lanlan, et al.
Publicado: (2018)

KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
por: Wang, Lei, et al.
Publicado: (2014)

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
por: Takahashi, N, et al.
Publicado: (2014)

Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis
por: Hsieh, Meng-Chiao, et al.
Publicado: (2018)

AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
por: Ye, Hua, et al.
Publicado: (2020)

A mechanism for the response of KRAS(G13D) expressing colorectal cancers to EGFR inhibitors
por: McFall, Thomas, et al.
Publicado: (2020)

Molecular Characterization of Acquired Resistance to KRAS(G12C)–EGFR Inhibition in Colorectal Cancer
por: Yaeger, Rona, et al.
Publicado: (2023)

Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer
por: Zocche, David M., et al.
Publicado: (2015)

BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy
por: Li, Zi-Nan, et al.
Publicado: (2020)

KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan
por: Awidi, Muhammad, et al.
Publicado: (2019)

Impact of KRAS Mutation on Survival Outcome of Patients With Metastatic Colorectal Cancer in Jordan
por: Alkader, Mohammad S, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v3h3u02qruvg5clbkks114gu9d